Kim S - Search Results

1

Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.

Kim SI, Joung JG, Kim YN, Park J, Park E, Kim JW, Lee S, Lee JB, Kim S, Choi CH, Kim HS, Lim J, Chung J, Kim BG, Lee JY. Kim SI, et al. Among authors: kim yn, kim bg, kim s, kim hs, kim jw. Gynecol Oncol. 2024 Mar;182:7-14. doi: 10.1016/j.ygyno.2023.12.029. Epub 2024 Jan 20. Gynecol Oncol. 2024. PMID: 38246047 Clinical Trial.

2

Impact of underweight after treatment on prognosis of advanced-stage ovarian cancer.

Kim SI, Kim HS, Kim TH, Suh DH, Kim K, No JH, Chung HH, Kim YB, Song YS. Kim SI, et al. J Immunol Res. 2014;2014:349546. doi: 10.1155/2014/349546. Epub 2014 Jun 24. J Immunol Res. 2014. PMID: 25050383 Free PMC article.

3

Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.

Kim SI, Lee JW, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Seo JS. Kim SI, et al. Gynecol Oncol. 2018 Feb;148(2):375-382. doi: 10.1016/j.ygyno.2017.12.005. Epub 2017 Dec 9. Gynecol Oncol. 2018. PMID: 29233531

4

Robot-assisted anterior pelvic exenteration in vulvovaginal malignant melanoma.

Kim SI, Lee S, Jeong CW, Kim HS. Kim SI, et al. Among authors: kim hs. Gynecol Oncol. 2018 Feb;148(2):430-431. doi: 10.1016/j.ygyno.2017.12.022. Epub 2017 Dec 21. Gynecol Oncol. 2018. PMID: 29276058

5

LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data.

Kim SI, Lee JW, Lee N, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Seo JS. Kim SI, et al. BMC Cancer. 2018 May 2;18(1):494. doi: 10.1186/s12885-018-4429-z. BMC Cancer. 2018. PMID: 29716549 Free PMC article.

6

Robot-assisted inguinal sentinel lymph node biopsy in primary yolk sac tumor of the vulva.

Kim SI, Kim R, Seong J, Kim HS. Kim SI, et al. Surg Oncol. 2018 Sep;27(3):520. doi: 10.1016/j.suronc.2018.05.035. Epub 2018 Jun 8. Surg Oncol. 2018. PMID: 30217313

7

Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer.

Kim SI, Song M, Hwangbo S, Lee S, Cho U, Kim JH, Lee M, Kim HS, Chung HH, Suh DS, Park T, Song YS. Kim SI, et al. Among authors: kim hs, kim jh. Cancer Res Treat. 2019 Jul;51(3):1144-1155. doi: 10.4143/crt.2018.508. Epub 2018 Nov 20. Cancer Res Treat. 2019. PMID: 30453728 Free PMC article.

8

Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.

Kim SI, Cho JH, Seol A, Kim YI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS. Kim SI, et al. Gynecol Oncol. 2019 Apr;153(1):3-12. doi: 10.1016/j.ygyno.2019.01.008. Epub 2019 Jan 12. Gynecol Oncol. 2019. PMID: 30642625

9

Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer.

Lee N, Kim SI, Lee M, Kim HS, Kim JW, Park NH, Song YS. Lee N, et al. In Vivo. 2019 May-Jun;33(3):863-868. doi: 10.21873/invivo.11551. In Vivo. 2019. PMID: 31028209 Free PMC article.

10

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.

Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS. Kim SI, et al. J Ovarian Res. 2019 May 7;12(1):40. doi: 10.1186/s13048-019-0511-7. J Ovarian Res. 2019. PMID: 31064392 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

119,534 results

Search Page